Cervical Cancer
Conditions
Interventions
experimental group:concurrent chemoradiotherapy combined with consolidation chemotherapy
Sponsors
Fudan University Shanghai Cancer Center
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 - 70, ECOG performance status 0 - 2; 2. Clinical stage IA2, IB, or IIA, receive extensive abdominal hysterectomy with pelvic lymphadenectomy with or without para-aortic lymphadenectomy/biopsy; 3. The postoperative pathology is cervical squamous cell carcinoma, cervical adenosquamous cell carcinoma or cervical adenocarcinoma; 4. Lymph node metastasis confirmed by postoperative pathology; 5. No previous radiotherapy / chemotherapy; 6. No severe hematopoiesis, heart, lung, liver and kidney dysfunction and immune deficiency: bilirubin = 1.5 × ULN, AST or ALT = 2.5 × ULN, creatinine = 1.5 times the upper limit of normal value, HB = 10.0 g / dl, WBC = 3.5 × 109 / L, ANC = 2.0 × 109 / L, platelet = 100 × 109 / L; 7. Written informed consent; 8. Cooperate with follow-up; 9. Expected lifetime = 6 months.
Exclusion criteria
Exclusion criteria: 1. Positive parametrial and vaginal incisions confirmed by postoperative pathology; 2. Suffering from other malignant tumors; 3. Known allergy to cisplatin / carboplatin and paclitaxel; 4. Clinically serious (i.e. active) heart disease, such as symptomatic coronary heart disease, NYHA class II or more congestive heart failure or serious arrhythmia requiring drug intervention, or a history of myocardial infarction within the last 12 months; 5. Organ transplant patients in need of immunosuppressive therapy; 6. Severe uncontrolled repeated infection, or other serious complications; 7. Distant metastasis detected by CT, MRI and/or PET-CT; 8. Participated in other clinical trials; 9. Drug addiction, chronic alcoholism or AIDS.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| OS;PFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Toxic reaction;Quality of life; | — |
Countries
China
Contacts
Public ContactWu Xiaohua
Fudan University Shanghai Cancer Center
Outcome results
None listed